[CAS NO. 1095253-39-6]  ARQ 621

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1095253-39-6]

Store
Catalog
SLK-S7355
Brand
Selleck
CAS
1095253-39-6

DESCRIPTION [1095253-39-6]

Overview

MDL-
Molecular Weight552.43
Molecular FormulaC28H24Cl2FN5O2
SMILES-

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

1 mg5 mg10 mg
1 mM1.8102 mL9.0509 mL18.1018 mL
5 mM0.3620 mL1.8102 mL3.6204 mL
10 mM0.1810 mL0.9051 mL1.8102 mL
50 mM0.0362 mL0.1810 mL0.3620 mL

Description

ARQ 621 is an allosteric, and selective inhibitor. Phase 1.

Targets

Eg5 mitotic motor protein [1]

In vitro

ARQ 621 demonstrates anti-tumor activity against a wide range of human cancer cell lines in vitro, including colon, lung, endometrial, bladder, and hematologic cancer cell lines, with significantly less cytotoxicity against hematopoietic cells.

In vivo

ARQ 621, as a novel clinical stage drug candidate, inhibits a number of xenografts grown in athymic mice, such as pancreatic, breast, prostate, and ovarian carcinomas with no hematological changes. Furthermore, for ARQ 621, there is no envidence of bone marrow toxicity in pre-clinical mouse efficacy models or safety studies in rats and dogs.